Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Luneau Technology and Optovue to merge

The companies suggest the merger will provide a “complete offering” for eye care professionals, with devices for the front and back of the eye

red and black frames
Getty/DuxX
Healthcare device manufacturer, Luneau Technology, and medical device company, Optovue, have formed a definitive agreement to merge.

The companies suggest the merger will create a “complete offering” for eye care professionals, bringing together its technologies and with a key focus on telehealth solutions.

CEO of Luneau Technology, Dr Marc Abitbol, will lead the combined company and Peter Wyles will continue in his role as CEO of Optovue.

The two companies will continue to deliver products through their existing channels and will initially focus on sharing good practice.

In addition to providing a full product range to customers, it is suggested the merger would enable the companies to leverage industry expertise and strengthen their international reach, with a joint vision of becoming the “first-choice partner for primary eye care” and improving access to visual health.

Luneau Technology develops and manufactures devices for eye care professionals, with its flagship brand, Visionix, specialising in diagnosis and refraction, while Optovue is focused on the advancement and commercialisation of high-speed optical coherence tomography (OCT) and OCT Angiography technology.

Commenting on the merger, Abitbol said: “It will benefit us, our clients and patients. OCT is the next technology we were looking for, and it fits beautifully into our product offering.

“By joining forces with Optovue, we’ll be able to offer a significantly improved customer experience with full front- and back-of-the-eye platforms,” he added.

Optovue’s Wyles suggested the merger makes sense for both companies, continuing: “We are thrilled to work together toward our common vision, while at the same time, significantly optimising the customer experience.”

The merger remains subject to customary conditions for completion and legal approvals.